239 related articles for article (PubMed ID: 28400290)
1. Downstream drug product processing of itraconazole nanosuspension: Factors influencing drug particle size and dissolution from nanosuspension-layered beads.
Parmentier J; Tan EH; Low A; Möschwitzer JP
Int J Pharm; 2017 May; 524(1-2):443-453. PubMed ID: 28400290
[TBL] [Abstract][Full Text] [Related]
2. Downstream drug product processing of itraconazole nanosuspension: Factors influencing tablet material properties and dissolution of compacted nanosuspension-layered sugar beads.
Tan EH; Parmentier J; Low A; Möschwitzer JP
Int J Pharm; 2017 Oct; 532(1):131-138. PubMed ID: 28859940
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of itraconazole nano-co-crystals into multiparticulate oral dosage forms.
Huang Z; Staufenbiel S; Bodmeier R
Eur J Pharm Biopharm; 2022 Jul; 176():75-86. PubMed ID: 35598769
[TBL] [Abstract][Full Text] [Related]
4. Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beads.
Kayaert P; Anné M; Van den Mooter G
J Pharm Pharmacol; 2011 Nov; 63(11):1446-53. PubMed ID: 21988425
[TBL] [Abstract][Full Text] [Related]
5. Formulation and drying of miconazole and itraconazole nanosuspensions.
Cerdeira AM; Mazzotti M; Gander B
Int J Pharm; 2013 Feb; 443(1-2):209-20. PubMed ID: 23291552
[TBL] [Abstract][Full Text] [Related]
6. Improved oral bioavailability of core-shell structured beads by redispersion of the shell-forming nanoparticles: preparation, characterization and in vivo studies.
Yao Q; Tao X; Tian B; Tang Y; Shao Y; Kou L; Gou J; Li X; Yin T; Tang X
Colloids Surf B Biointerfaces; 2014 Jan; 113():92-100. PubMed ID: 24060933
[TBL] [Abstract][Full Text] [Related]
7. Fast dissolution of poorly water soluble drugs from fluidized bed coated nanocomposites: Impact of carrier size.
Azad M; Moreno J; Bilgili E; Davé R
Int J Pharm; 2016 Nov; 513(1-2):319-331. PubMed ID: 27639622
[TBL] [Abstract][Full Text] [Related]
8. Formulation and performance of Irbesartan nanocrystalline suspension and granulated or bead-layered dried powders - Part I.
Meruva S; Thool P; Shah S; Karki S; Bowen W; Ghosh I; Kumar S
Int J Pharm; 2019 Sep; 568():118189. PubMed ID: 30851385
[TBL] [Abstract][Full Text] [Related]
9. Formulation of itraconazole nanococrystals and evaluation of their bioavailability in dogs.
De Smet L; Saerens L; De Beer T; Carleer R; Adriaensens P; Van Bocxlaer J; Vervaet C; Remon JP
Eur J Pharm Biopharm; 2014 May; 87(1):107-13. PubMed ID: 24388913
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods.
Kim JH; Jang SW; Han SD; Hwang HD; Choi HG
Pharmazie; 2011 Jul; 66(7):491-5. PubMed ID: 21812323
[TBL] [Abstract][Full Text] [Related]
11. Production and in vitro characterization of solid dosage form incorporating drug nanoparticles.
Basa S; Muniyappan T; Karatgi P; Prabhu R; Pillai R
Drug Dev Ind Pharm; 2008 Nov; 34(11):1209-18. PubMed ID: 18720147
[TBL] [Abstract][Full Text] [Related]
12. Nanonized itraconazole powders for extemporary oral suspensions: Role of formulation components studied by a mixture design.
Foglio Bonda A; Rinaldi M; Segale L; Palugan L; Cerea M; Vecchio C; Pattarino F
Eur J Pharm Sci; 2016 Feb; 83():175-83. PubMed ID: 26742430
[TBL] [Abstract][Full Text] [Related]
13. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
14. Design and Evaluation of Eudragit RS-100 Based Itraconazole Nanosuspension for Ophthalmic Application.
Pawar P; Duduskar A; Waydande S
Curr Drug Res Rev; 2021; 13(1):36-48. PubMed ID: 32990554
[TBL] [Abstract][Full Text] [Related]
15. Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.
Alshweiat A; Katona G; Csóka I; Ambrus R
Eur J Pharm Sci; 2018 Sep; 122():94-104. PubMed ID: 29908301
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the release kinetics of drug nanocrystal-loaded pellet formulations.
Möschwitzer JP; Müller RH
Drug Dev Ind Pharm; 2013 May; 39(5):762-9. PubMed ID: 22803784
[TBL] [Abstract][Full Text] [Related]
17. An Intensified Vibratory Milling Process for Enhancing the Breakage Kinetics during the Preparation of Drug Nanosuspensions.
Li M; Zhang L; Davé RN; Bilgili E
AAPS PharmSciTech; 2016 Apr; 17(2):389-99. PubMed ID: 26182907
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a riboflavin non-aqueous nanosuspension prepared by bead milling for cutaneous application.
Sato T; Takeuchi H; Sakurai T; Tanaka K; Matsuki K; Higashi K; Moribe K; Yamamoto K
Chem Pharm Bull (Tokyo); 2015; 63(2):88-94. PubMed ID: 25748779
[TBL] [Abstract][Full Text] [Related]
19. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
20. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
